Atezolizumab + chemo gets greenlight from HSA for PD-L1+ TNBC
Atezolizumab, in combination with the chemotherapy nab-paclitaxel, has been approved by the Singapore Health Sciences Authority (HSA) for the first-line treatment of unresectable locally advanced or metastatic, PD-L1-positive (PD-L1+) triple-negative breast cancer (TNBC) — adding to the growing market list this drug has been granted approval for TNBC.
